The newly-opened sites in Wetherby and Cambridge, UK adds a total of 9,000 sq ft of laboratory and manufacturing space - almost doubling Avacta Group’s current footprint - and focuses on the development of its Affimer technology.
The Affirmer platform – acquired when Avacta bought Aptuscan in 2012 - is based on a small human protein that can be engineered to bind with high specificity and affinity to a wide range of protein targets, and according to chief commercial officer Philippe Cotrel involves a well-established bacterial expression process.
“The process for producing Affimer proteins is a straightforward bacterial expression process using E.coli. It is currently done using benchtop equipment and can be easily scaled up using standard bioprocessing equipment,” he told Biopharma-Reporter.com.
“At this stage, production is not a bottleneck and the expansion is to support our increased therapeutic focus as well as our custom service and reagent R&D efforts.”
The Wetherby facility will focus on reagents for research and diagnostics, as well as providing a third party service, while the Cambridge plant will focus on therapeutics both for both internal and co-development pipelines.
But though Affimer therapeutics are still in the pre-clinical stage of development, Cotrel said such products have “significant potential benefits” over traditional antibodies for therapeutic use.
“Affimer biotherapeutics can be engineered to have tuneable half-life, which can be tailored according to therapeutic need,” he said, adding they are smaller than antibodies and “therefore have the potential to exhibit higher tissue penetration.”
He continued, saying “bi-specificity is much easier to achieve with Affimer biotherapeutics vs antibodies, and fusions to other functional proteins are simple to generate and manufacture, enabling combination targets.”